SOURCE: Trident Brands Inc.

Trident Brands Inc.

December 15, 2015 09:00 ET

Trident Brands Appoints Dr. Julian E. Bailes Special Advisor to Brain Armor

BROOKFIELD, WI--(Marketwired - Dec 15, 2015) - Trident Brands, Inc. (OTCQB: TDNT), is pleased to announce the appointment of Dr. Julian E. Bailes as a Special Advisor to Brain Armor®.

Dr. Bailes is a nationally recognized leader in the field of neurosurgery and conducts research on the impact of brain injury on neurological function. Dr. Bailes is the Chairman of the Department of Neurosurgery at NorthShore University HealthSystem, Co-Director of the NorthShore Neurological Institute, and a Clinical Professor of Neurosurgery at the University of Chicago Pritzker School of Medicine.

"There is nothing more important than brain and cognitive health. There is a significant amount of research currently being done in the area of concussion treatment and prevention. I am pleased to work with Brain Armor to highlight the benefits to overall health and neurological function by DHA, which is the primary omega-3 fatty acid in the brain. Numerous studies have shown the positive effects of DHA on brain activity" said Dr. Bailes.

Brain Armor is a plant-based DHA supplement designed specifically for the needs of athletes. Brain Armor is certified through NSF International's Certified for Sport® Program, which screens for banned substance and is used by professional and amateur sports leagues worldwide.

Trident Brands holds an exclusive worldwide license from Royal DSM to market Brain Armor.

About Trident Brands, Inc.

Trident Brands, Inc. (TDNT) is an emerging growth company focused on identifying and building growth brands in dynamic consumer segments. Trident is currently targeting growth opportunities in brand and consolidated licenses, consumer goods such as functional foods, supplements, and beverages, life science technologies that have applications in consumer products, and intellectual property and/or licenses in recognized brand platforms. TDNT holds an exclusive worldwide license from Royal DSM to market Brain Armor®. TDNT also holds an exclusive license from Everlast Worldwide to market and sell products in the nutritional foods and supplements category under the Everlast brand. Trident's licensing agreement enables it to introduce a portfolio of nutritional products in categories such as supplements and functional foods using this famous brand mark. Everlast is owned by International Brand Management and Licensing (IBML).

About Julian E. Bailes, MD

Julian E. Bailes, Jr. M.D. is the Chairman of the Department of Neurosurgery at NorthShore University HealthSystem, Co-Director of the NorthShore Neurological Institute, and a Clinical Professor of Neurosurgery at the University of Chicago Pritzker School of Medicine. Dr. Bailes is a nationally recognized leader in the field of neurosurgery and conducts research on the impact of brain injury on brain function. He has performed both clinical and experimental studies on mild traumatic brain injury or concussion, particularly in athletes and military veterans. He has expertise in cerebrovascular, epilepsy surgery, and brain tumor and skull base surgery and is ranked in the top 1 percent of neurosurgeons by U.S. News & World Report. In 2014 he was chosen as a Chicago top neurosurgeon by Chicago Magazine. Dr. Bailes has more than 200 manuscripts published in peer-reviewed journals, and has authored five books concerning various aspects of neurological surgery. He has received more than $27 million in research funding during his career, and is Chairman of the Medical Advisor Board of Pop Warner Football, the nation's largest and oldest youth football organization, as well as being an advisor to the NFL Players' Association and the NCAA on neurological injuries.

About Royal DSM
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about EUR 10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

About NSF
NSF International, an independent, not-for-profit organization, certifies products and writes standards for food, water and consumer goods to minimize adverse health effects and protect the environment (http://www.nsf.org). Founded in 1944, NSF is committed to protecting human health and safety worldwide and operates in more than 120 countries. NSF is a World Health Organization Collaborating Centre for Food and Water Safety and Indoor Environment.

NSF's Dietary Supplement Certification program verifies that what is on the label is in the bottle and that the product does not contain undeclared ingredients or contaminants. NSF's Athletic Banned Substances Certification program builds on the dietary supplement certification program by including screening that ensures the product does not contain banned or prohibited substances.

MLB, the MLB Player's Association, NFL, the NFL Player's Association, PGA, LPGA and the CCES have all chosen NSF's Certified for Sport™ program to help verify the products their athletes use are safer and free of banned substances.

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995 that are not historical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and the Company's future performance, operations, and products. Such statements involve known and unknown risks, uncertainties and other factors that could cause the Company's actual results to differ materially from the results expressed or implied by such statements. Such risks and uncertainties include, without limitation, market acceptance of the Company's forthcoming line of nutritional products; the Company's compliance with applicable Food and Drug Administration regulations; the Company's reliance on third-party contractors to mix and produce its products; the Company's ability to develop an effective marketing strategy; the Company's ability to control advertising and marketing costs; the Company's ability to develop and increase awareness of its forthcoming brands; the success of the Company's marketing focus to retail buyers; the Company's exposure to product liability claims and intellectual property claims from third parties; and the Company's reliance on the expected growth in demand for its products. For a discussion of these and other risks and uncertainties see "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public filings with the SEC. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

Contact Information